Full-Time

Director – Strategic Support EP & NV

Strategic Planning

Posted on 10/1/2025

Deadline 10/13/25
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$146k - $251.8k/yr

+ Bonus

Irvine, CA, USA

Hybrid

Hybrid work arrangement indicated by #LI-HYBRID.

Category
Business & Strategy (2)
,
Required Skills
Sales
Marketing
Requirements
  • Bachelor’s degree required; Advance degree preferred (MBA).
  • 8-10+ years of professional experience in sales, marketing, R&D, Finance, or in house/functional leadership roles. Experience should embrace expertise on successfully leading critical-to-business initiatives such as product launches, KOL relationships, and driving and executing on innovation projects.
  • Proven track record and ability to lead cross functional projects, chartering and executing on business transformational projects that lead to significant improvement in our ability to execute on strategic mandate or create competitive advantages.
  • Leadership traits aligned with our core values: Connect, Shape, Grow.
  • Ability to influence and drive change, creating followership, enthusiasm and alignment.
  • Global mindset advocate, Multicultural thinking.
  • Focus on executing and delivering on commitments with high attention to detail.
  • Ability to work independently, proactively, and with senior executives is required.
  • Effective verbal and written communication skills, including presentation skills.
  • Demonstrated ability to work in a matrix environment where a high degree of collaboration is needed.
  • Must be highly organized with the ability to manage multiple projects/tasks simultaneously and effectively prioritize projects and tasks. Attention to detail required.
  • Advanced analytical and problem-solving skills; tenacity to learn, analyze, and resolve complex situations.
  • Must have strong detail orientation.
  • Strong financial acumen.
  • Strong sense of urgency.
  • Ability to travel domestically and internationally up to 30%, including some weekend travel.
Responsibilities
  • Senior Leader Engagement & Collaboration: this role will have the ability to influence our senior leaders in reaching agreement and leading senior level teams without direct authority. This role will work directly with senior stakeholders across the organization, including members of the EP & NV LT & MDLT as well as leaders within their organizations. Will prepare Company Group Chair (CGC) for all MTLT interactions.
  • Strategic Communications and Integrated Business Narrative Development: this role must be able to synthesize vast amounts of data, perspectives, and other nuanced information into a clear, concise, and compelling story to help drive alignment across the organization. Communication audiences will include worldwide, executive and external audiences.
  • Project Management: this role will support critical initiatives linked to the overall EP & NV strategy. These responsibilities may include leading and delivering on complex transformational & strategic projects; conducting relevant research, identifying insights and doing analyses; creating communication materials; designing and executing stakeholder engagement plans to drive alignment with senior leaders; developing pragmatic, executable strategies and leading the implementation of these; and being accountable for successful project delivery and demonstrated business impact.
  • EP & NV LT Governance: this role will be responsible for supporting the CGC in setting agendas, working with teams to define issues requiring review by the EP & NV LT and the timing for these reviews, tracking follow up assignments and ensuring appropriate resolution of open issues, summarizing committee proceedings, setting a general calendar for the EP & NV LT and performing relevant metrics reviews and committee evaluations periodically.
  • Meetings cadence and EP & NV LT board meetings: this role will have the ability to set the cadence of meetings for the EP & NV LT, coordinate and sync with the MDLT schedule, drive agendas and action items.
  • Engage in external meetings, (advisory boards, congresses, customers / KOL meetings) ensure delivery of follow-up actions.
  • Communications: this role will liaise with Global Communications to ensure clear and consistent messaging for organization in all Town Halls and Senior Executive forums. Will manage graphic design office.
  • Confidentiality: this role will be exposed to vast amounts of confidential data where absolute confidentiality is a must.
  • Connector: this role will be required to connect across many functions / platforms and regions and will act as a sounding board for the CGC office.
Desired Qualifications
  • Ability to influence and drive change, creating followership, enthusiasm and alignment.
  • Global mindset advocate, Multicultural thinking.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE